Harnessing the restorative potential of novel CNS therapeutics

Our strategy focuses on addressing demyelination and neuroinflammation, which are key drivers of diseases such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and various demyelinating and degenerative disorders.

We strive to develop first-in-class and best-in-class oral small molecule therapies for those suffering from CNS diseases. Successful CNS drugs demand a wide therapeutic margin and high CNS distribution to ensure a favorable safety profile and clinically meaningful efficacy. By leveraging our drug discovery expertise, we identify potent, selective, and brain-penetrant compounds that can address therapeutically relevant targets. We are committed to using biomarker-guided precision neurology to deliver innovative therapies to the most appropriate patient populations.